TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1553580

Group type: EXPERIMENTAL
Intervention: IFN-alpha alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: IFN-alpha combined with IFN-gamma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IFN-alpha and TNF-alpha
Number of subjects: 0
Study: 3963017

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 200 mg per day (administered three times daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 150 mg per day (administered twice daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Number of subjects: 90

Group type: COMPARATOR
Intervention: Phenylbutazone 300 mg per day
Number of subjects: 90
Study: 29967045

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure treatment
Number of subjects: 4733

Group type: COMPARATOR
Intervention: Standard blood pressure treatment
Number of subjects: 4733
Study: 26493492

Group type: EXPERIMENTAL
Intervention: Saracatinib
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24818182

Group type: EXPERIMENTAL
Intervention: Ceramide-containing cleanser and moisturizer regimen
Number of subjects: 151
Study: 22205149

Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Calcitriol
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Hormone therapy with calcitriol
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Polymorphisms of estrogen receptor α
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Polymorphisms of vitamin D receptor
Number of subjects: 489
Study: 20638901

Group type: EXPERIMENTAL
Intervention: Total Laparoscopic Hysterectomy (TLH)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Total Abdominal Hysterectomy (TAH)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: TLH
Number of subjects: 283

Group type: COMPARATOR
Intervention: TAH
Number of subjects: 283
Study: 18433525

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 60
Study: 15964329

Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 20

Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia
Number of subjects: 20
Study: 11788660

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg every 8 h for 7 d)
Number of subjects: 6
Study: 10235511

Group type: EXPERIMENTAL
Intervention: WR 6026 at 120 mg/day for 21 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: WR 6026 at 150 mg/day for >19 days
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: WR 6026
Number of subjects: 49
Study: 8767368

Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen administration
Number of subjects: 22
Study: 2024744

Group type: EXPERIMENTAL
Intervention: Continuous lumbar plexus block with 0.5% bupivacaine and adrenaline (0.3 ml/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Conventional opioid analgesia (control group)
Number of subjects: 29
Study: 7014058

Group type: EXPERIMENTAL
Intervention: Aspirin, 600 mg, b.i.d.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combination of aspirin and hydroxychloroquine (Plaquenil), 300 mg, b.i.d.
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 31259390

Group type: EXPERIMENTAL
Intervention: Breath-based classifier using a nanomaterial-based sensor array
Number of subjects: 726
Study: 28966304

Group type: EXPERIMENTAL
Intervention: Mild hypothermia therapy (34‐36°C)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without mild hypothermia therapy)
Number of subjects: 20
Study: 25467190

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg + morphine 60 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) placebo + morphine 60 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GEn) 600 mg + morphine placebo
Number of subjects: 18

Group type: COMPARATOR
Intervention: Gabapentin enacarbil (GEn) alone
Number of subjects: 18

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination treatment (GEn + morphine)
Number of subjects: 18
Study: 23780900

Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (4 min at -110 °C)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Cold water immersion (8 °C)
Number of subjects: 10
Study: 21317209

Group type: EXPERIMENTAL
Intervention: Fluoride-containing CPP-ACP paste (MI Paste Plus) with Transbond XT
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Non-fluoride CPP-ACP paste (MI Paste) with Transbond XT
Number of subjects: 66

Group type: COMPARATOR
Intervention: No pre-treatment with etch-and-rinse adhesive system (Transbond XT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: No pre-treatment with self-etching adhesive system (Transbond Plus)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Fluoride-containing CPP-ACP paste (MI Paste Plus) with Transbond Plus
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Non-fluoride CPP-ACP paste (MI Paste) with Transbond Plus
Number of subjects: 66
Study: 19653749

Group type: EXPERIMENTAL
Intervention: Action execution with visual go signal inducing apparent rotational motion (clockwise or counterclockwise)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants prepared manipulation actions but signaled their stimulus detections with a foot response
Number of subjects: 0
Study: 17845276

Group type: EXPERIMENTAL
Intervention: Topiramate (100-400 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 14693611

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 34
Study: 12067142

Group type: EXPERIMENTAL
Intervention: Investigational drug for 24 weeks
Number of subjects: 302

Group type: COMPARATOR
Intervention: Matched placebo for 24 weeks
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Extension study
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Overall attrition during 50-week period
Number of subjects: 302
Study: 9526939

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Endotracheal intubation
Number of subjects: 61
Study: 8009700

Group type: COMPARATOR
Intervention: Intensive multidisciplinary functional restoration program (project A)
Number of subjects: 238

Group type: COMPARATOR
Intervention: Intensive multidisciplinary functional restoration program (project B)
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Intensive multidisciplinary functional restoration program
Number of subjects: 238
Study: 2570956

Group type: EXPERIMENTAL
Intervention: Ceftazidime (120 mg/kg/day)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Conventional therapy (chloramphenicol 100 mg/kg/day, doxycycline 4 mg/kg/day, trimethoprim 10 mg/kg/day, and sulphamethoxazole 50 mg/kg/day)
Number of subjects: 161
Study: 434310

Group type: EXPERIMENTAL
Intervention: Metronidazole (Flagyl)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Quinacrine (Atabrine)
Number of subjects: 160
Study: 31397128

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hyaluronic acid sodium eye drops
Number of subjects: 60
Study: 28524705

Group type: EXPERIMENTAL
Intervention: Intensive individualized nutritional and educational interventions during the entire course of chemotherapy
Number of subjects: 144

Group type: COMPARATOR
Intervention: Basic nutrition care and health education during hospitalization
Number of subjects: 144
Study: 25039574

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB) with salbutamol and prednisolone
Number of subjects: 347

Group type: COMPARATOR
Intervention: Salbutamol and prednisolone alone (Control)
Number of subjects: 347
Study: 23777201

Group type: EXPERIMENTAL
Intervention: High-Intensity Treatment (HIT)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Low-Intensity Treatment (LIT)
Number of subjects: 300
Study: 21864343

Group type: EXPERIMENTAL
Intervention: SP+AS+PQ (single dose 0.75 mg/kg)
Number of subjects: 3457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3457
Study: 19722772

Group type: EXPERIMENTAL
Intervention: Desferrioxamine + Deferiprone (n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Desferrioxamine (n=35)
Number of subjects: 70
Study: 17869635

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 220 mg
Number of subjects: 3494

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate 150 mg
Number of subjects: 3494

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 3494

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate and Enoxaparin
Number of subjects: 3494
Study: 16855074

Group type: EXPERIMENTAL
Intervention: FTY720 1.25 mg
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: FTY720 5 mg
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: FTY720 (1.25 mg or 5 mg)
Number of subjects: 66
Study: 12773727

Group type: EXPERIMENTAL
Intervention: TTM based self help manuals and sessions with an interactive computer program
Number of subjects: 918

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 918
Study: 10426879

Group type: EXPERIMENTAL
Intervention: Statin treatment (Simvastatin)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Statin treatment (not specified)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Statin treatment (Pravastatin)
Number of subjects: 3
Study: 7482385

Group type: EXPERIMENTAL
Intervention: Prednisone 30 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Prednisone 60 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Dextroamphetamine 15 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 1951176

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 200 mg/m2, 5-fluorouracil (FU) 600 mg/m2, folinic acid (FA) 200 mg/m2, administered every 2 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Side effects of the treatment
Number of subjects: 30
Study: 7056271

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 15
Study: 28533100

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC) treatment, performed twice a day for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 27914656

Group type: EXPERIMENTAL
Intervention: 25 mg oral omecamtiv mecarbil twice daily (fixed-dose group)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: 25 mg twice daily titrated to 50 mg twice daily (pharmacokinetic-titration group)
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic-titration group
Number of subjects: 299

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 299
Study: 23329162

Group type: EXPERIMENTAL
Intervention: Electrical mallet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hand mallet (Control)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups (Electrical mallet and Hand mallet)
Number of subjects: 46
Study: 24895719

Group type: EXPERIMENTAL
Intervention: Educational intervention for general practitioners (structured formative course)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 185
Study: 20664616

Group type: EXPERIMENTAL
Intervention: n-3 fatty acid enriched eggs
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: organic eggs
Number of subjects: 20

Group type: COMPARATOR
Intervention: no egg control
Number of subjects: 20
Study: 18332454

Group type: EXPERIMENTAL
Intervention: Biocompatible PDFs with neutral pH and low glucose degradation products (GDPs)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Conventional PDFs
Number of subjects: 104
Study: 16105530

Group type: EXPERIMENTAL
Intervention: 0.5 microg of calcitriol twice per day (group A)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: 1 microg of calcitriol twice per day (group B)
Number of subjects: 417

Group type: COMPARATOR
Intervention: No calcitriol (group C)
Number of subjects: 417
Study: 11834648

Group type: EXPERIMENTAL
Intervention: 40% oxygen during exercise
Number of subjects: 17

Group type: COMPARATOR
Intervention: Air during exercise
Number of subjects: 17
Study: 10512314

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Naltrexone and Placebo
Number of subjects: 132
Study: 7726258

Group type: EXPERIMENTAL
Intervention: Meconium-stained amniotic fluid (n = 28)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no meconium-stained amniotic fluid, n = 28)
Number of subjects: 56
Study: 2047050

Group type: EXPERIMENTAL
Intervention: Low-dose triphasic oral contraceptives (ethinyl estradiol and levonorgestrel)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Low-dose triphasic oral contraceptives (ethinyl estradiol and norethindrone)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control (nonhormonal contraception)
Number of subjects: 57
Study: 6110089

Group type: EXPERIMENTAL
Intervention: Oestrogen/gestagen treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Discontinuation of hormone therapy
Number of subjects: 94
Study: 31269644

Group type: EXPERIMENTAL
Intervention: Brain breaks activities (5 minutes per session for four months)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (no brain breaks)
Number of subjects: 335
Study: 26345405

Group type: EXPERIMENTAL
Intervention: Dutasteride (n = 25)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo (n = 24)
Number of subjects: 49
Study: 25761430

Group type: COMPARATOR
Intervention: Amlodipine (10 mg p.d.)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ranolazine (750 mg b.i.d.)
Number of subjects: 210
Study: 22759620

Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS) integrated into EHR
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 70
Study: 21323491

Group type: EXPERIMENTAL
Intervention: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy at dose step 4
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy at dose steps -2 and -1 (combined)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Tailored fluorouracil, epirubicin, and cyclophosphamide (FEC) therapy (all dose steps)
Number of subjects: 157
Study: 20306761

Group type: EXPERIMENTAL
Intervention: Chemical medicine (not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (inert pill)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biologically active drugs (not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCTs (not specified)
Number of subjects: 0
Study: 17093247

Group type: EXPERIMENTAL
Intervention: Chloroquine
Number of subjects: 210

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine
Number of subjects: 210
Study: 18210737

Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg/day for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 10929769

Group type: EXPERIMENTAL
Intervention: Nickel exposure (10 ppm for 1 week, then 100 ppm for 1 week)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Nickel exposure
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (vehicle exposure)
Number of subjects: 65
Study: 8819058

Group type: EXPERIMENTAL
Intervention: Elastic knee bandage
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Patients with patella dislocation (no intervention)
Number of subjects: 39
Study: 1478287

Group type: EXPERIMENTAL
Intervention: Transhiatal blunt esophagectomy (THE)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Transthoracic-abdominal esophagectomy (TTE)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Both groups (THE and TTE)
Number of subjects: 86
Study: 6143336

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 51

Group type: COMPARATOR
Intervention: Medicated subjects (14)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Task performance (accuracy in stimulus counting)
Number of subjects: 51
Study: 31664343

Group type: EXPERIMENTAL
Intervention: Immersive VR rehabilitation (60 minutes, 18 sessions, three days per week for six weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Conventional therapy (45 minutes) and sham VR program (15 minutes)
Number of subjects: 65
Study: 29318861

Group type: EXPERIMENTAL
Intervention: Heat Sensitive Moxibustion (HSM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Manual Acupuncture
Number of subjects: 70
Study: 25964246

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus radiotherapy (RT)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Luminal A subtype
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Luminal B subtype
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: High-risk subtypes
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Clinical low-risk luminal A tumors (n = 151)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: High-risk cohort (n = 341)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 501

Group type: EXPERIMENTAL
Intervention: Clinical risk group
Number of subjects: 501
Study: 23835207

Group type: EXPERIMENTAL
Intervention: Governmentally-led physical activity program (Youp'là Bouge) implemented in 58 child care centers, including training of educators, adaptation of the built environment, parental involvement, and daily physical activity from September 2009 to June 2010.
Number of subjects: 648

Group type: COMPARATOR
Intervention: Control group (n=201)
Number of subjects: 648
Study: 21911665

Group type: EXPERIMENTAL
Intervention: Ofloxacin, 0.3%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Azithromycin, 1%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Gatifloxacin, 0.3%
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Moxifloxacin hydrochloride, 0.5%
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (untreated fellow eye)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Overall treated eyes
Number of subjects: 24
Study: 19249176

Group type: EXPERIMENTAL
Intervention: Doripenem
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 0
Study: 16905817

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 112
Study: 15269581

Group type: EXPERIMENTAL
Intervention: Aquacel dressing
Number of subjects: 23

Group type: COMPARATOR
Intervention: Paraffin gauze dressing
Number of subjects: 23
Study: 11708243

Group type: EXPERIMENTAL
Intervention: Narrative Elaboration (NE) intervention using generic visual cue cards
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no NE intervention)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Narrative Elaboration (NE) intervention
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Low-SES preschoolers
Number of subjects: 99
Study: 9659302

Group type: EXPERIMENTAL
Intervention: Healing sessions (10 weekly sessions)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Waiting-list control
Number of subjects: 57
Study: 7654646

Group type: EXPERIMENTAL
Intervention: Flow cytometry
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Flow cytometry (assuming correct results)
Number of subjects: 43
Study: 2569062

Group type: EXPERIMENTAL
Intervention: Measurement of CVP when supine before fluid replacement
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Measurement of CVP when sat at 45 degrees before fluid replacement
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Measurement of CVP when supine after fluid replacement
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Measurement of CVP when sat at 45 degrees after fluid replacement
Number of subjects: 16
Study: 12713

Group type: EXPERIMENTAL
Intervention: Oxprenolol (40 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 31219254

Group type: EXPERIMENTAL
Intervention: Cold Water Immersion (CWI)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Static Rest (SR)
Number of subjects: 20
Study: 28971875

Group type: EXPERIMENTAL
Intervention: Simeprevir (150 mg QD) + Sofosbuvir (400 mg QD) + Ledipasvir (90 mg QD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg QD) + Sofosbuvir (400 mg QD)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Simeprevir-sofosbuvir-ledipasvir regimen
Number of subjects: 40
Study: 25590761

Group type: EXPERIMENTAL
Intervention: Bifrontal ECT (BF)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Right Unilateral ECT (RUL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Both BF and RUL ECT
Number of subjects: 73
Study: 23585901

Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (90 min/day, 2 days/week, for 6 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Education control group (attended two education classes)
Number of subjects: 100
Study: 22253488

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 34

Group type: COMPARATOR
Intervention: Wavefront-guided PRK
Number of subjects: 34
Study: 19433558

Group type: EXPERIMENTAL
Intervention: Posaconazole administered via nasogastric tube (400 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posaconazole administered orally (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both administration routes (oral and nasogastric tube)
Number of subjects: 0
Study: 16491580

Group type: EXPERIMENTAL
Intervention: 3 mg x kg(‐1) x d(‐1) caffeine (G3)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: 6 mg x kg(‐1) x d(‐1) caffeine (G6)
Number of subjects: 59

Group type: COMPARATOR
Intervention: 0 mg x kg(‐1) x d(‐1) caffeine (G0)
Number of subjects: 59
Study: 12574202

Group type: EXPERIMENTAL
Intervention: Ghrelin (3.3 microg/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 8
Study: 10325289

Group type: EXPERIMENTAL
Intervention: Danazol 600 mg daily for 3 months
Number of subjects: 77

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 77